AbCellera Biologics annual return on equity
2020
2021
2022
2023
2024
2025
AbCellera Biologics Return on Equity (ROE) Growth & History (ABCL)
AbCellera Biologics's return on equity was −14.47% for fiscal 2025.
View full AbCellera Biologics company overviewAbCellera Biologics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −14.47% | +0.27 pp |
| 2024 | 2024-12-31 | −14.75% | −2.48 pp |
| 2023 | 2023-12-31 | −12.27% | −26.31 pp |
| 2022 | 2022-12-31 | 14.03% | −2.50 pp |
| 2021 | 2021-12-31 | 16.53% | −11.75 pp |
| 2020 | 2020-12-31 | 28.29% | — |
AbCellera Biologics quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −6.04% | −2.62 pp |
| Q1 2026 | 2026-03-31 | −4.53% | −0.14 pp |
| Q4 2025 | 2025-12-31 | −0.93% | +2.28 pp |
| Q3 2025 | 2025-09-30 | −5.80% | −1.13 pp |
| Q2 2025 | 2025-06-30 | −3.42% | −0.13 pp |
| Q1 2025 | 2025-03-31 | −4.39% | −0.83 pp |
| Q4 2024 | 2024-12-31 | −3.21% | +0.83 pp |
| Q3 2024 | 2024-09-30 | −4.67% | −2.26 pp |
| Q2 2024 | 2024-06-30 | −3.30% | −0.76 pp |
| Q1 2024 | 2024-03-31 | −3.56% | −0.27 pp |
| Q4 2023 | 2023-12-31 | −4.04% | −1.63 pp |
| Q3 2023 | 2023-09-30 | −2.41% | −4.57 pp |
| Q2 2023 | 2023-06-30 | −2.54% | −1.98 pp |
| Q1 2023 | 2023-03-31 | −3.29% | −18.38 pp |
| Q4 2022 | 2022-12-31 | −2.41% | −8.47 pp |
| Q3 2022 | 2022-09-30 | 2.16% | +4.39 pp |
| Q2 2022 | 2022-06-30 | −0.56% | −0.32 pp |
| Q1 2022 | 2022-03-31 | 15.10% | +1.98 pp |
| Q4 2021 | 2021-12-31 | 6.06% | −21.77 pp |
| Q3 2021 | 2021-09-30 | −2.23% | — |
| Q2 2021 | 2021-06-30 | −0.24% | — |
| Q1 2021 | 2021-03-31 | 13.11% | — |
| Q4 2020 | 2020-12-31 | 27.83% | — |
AbCellera Biologics return on equity trends
Over the last five fiscal years, AbCellera Biologics's return on equity decreased from 28.29% to −14.47%, a change of −42.76 percentage points. The latest reported quarter, Q2 2026, shows −6.04%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbCellera Biologics source filings ↗